Method of treating liver disorders
AssigneeMediciNova, Inc.
InventorKazuko MATSUDA
Life of this patent
Estimating the term…
Abstract
A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for inhibiting liver steatosis, lobular inflammation, hepatic ballooning and hepatic scarring.
Claims40
A method of inhibiting steatosis in a patient suffering therefrom comprising administering to the patient in need thereof an effective amount of a compound of Formula (I):
- or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X1 and X2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen atom.
A method of inhibiting lobular inflammation in a patient suffering therefrom comprising administering to the patient in need thereof an effective amount of a compound of Formula (I):
- or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X1 and X2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen atom.
A method of inhibiting hepatic ballooning in a patient suffering therefrom comprising administering to the patient in need thereof an effective amount of a compound of Formula (I):
- or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X1 and X2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen atom.
A method of inhibiting hepatic scarring in a patient suffering therefrom comprising administering to the patient in need thereof an effective amount of a compound of Formula (I):
- or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X1 and X2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen atom.
A method of reducing and/or inhibiting elevated liver hydroxyproline levels in a patient suffering therefrom comprising administering to the patient in need thereof an effective amount of a compound of Formula (I):
- or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X1 and X2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen atom.
Dependencies are inferred from the claim text.